ログイン
ランキング
お知らせ
ログイン
文献詳細
特集 筋炎と壊死性筋症
文献概要
炎症性筋疾患は筋肉の炎症に加えて，皮膚，肺，心臓，関節にも障害を呈し得る疾患である。炎症性筋疾患は希少疾患であり，その病像や病態がさまざまであることから治療の標準化が難しい。治療の第一選択は副腎皮質ステロイド薬であり，治療抵抗例などに対して免疫抑制薬や免疫グロブリンが併用される。数多くの生物学的製剤の臨床試験が現在進行中であり，今後の炎症性筋疾患の治療選択肢となることが期待される。
参考文献
1)Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292: 403-407, 1975
2)Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, et al: 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14: 337-345, 2004
3)De Bleecker JL, De Paepe B, Aronica E, de Visser M, Amato A, et al: 205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies partⅡ 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord 25: 268-272, 2015
4)Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, et al: 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76: 1955-1964, 2017
5)厚生労働科学研究費補助金難治性疾患等政策研究事業難治性疾患政策研究事業 自己免疫疾患に関する調査研究班 多発性筋炎皮膚筋炎分科会: 多発性筋炎・皮膚筋炎治療ガイドライン. 診断と治療社, 東京, 2015, pp1-50
6)Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, et al: Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71: 710-713, 2012
7)Allenbach Y, Keraen J, Bouvier AM, Jooste V, Champtiaux N, et al: High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 139: 2131-2135, 2016
8)András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, et al: Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35: 438-444, 2008
9)Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG: Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med 92: 365-369, 1980
10)Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, et al: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329: 1993-2000, 1993
11)Miyasaka N, Hara M, Koike T, Saito E, Yamada M, et al: Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 22: 382-393, 2012
12)Bakewell CJ, Raghu G: Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139: 441-443, 2011
13)Marie I, Menard JF, Hatron PY, Hachulla E, Mouthon L, et al: Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken) 62: 1748-1755, 2010
14)Cherin P, Belizna C, Cartry O, Lascu-Dubos G, de Jaeger C, et al: Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. Autoimmun Rev 15: 281-286, 2016
15)Oddis CV, Reed AM, Aggarwal R, Rider LR, Ascherman DP, et al: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65: 314-324, 2013
16)Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, et al: Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66: 740-749, 2014
17)Schiffenbauer A, Garg M, Castro C, Pokrovnichka A, Joe G, et al: A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum 47: 858-864, 2018
18)Muscle Study Group: A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70: 427-436, 2011
19)Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, et al: Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phaseⅡb treatment delayed-start trial. Ann Rheum Dis 77: 55-62, 2018
20)Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, et al: Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50: 1344-1346, 2011
21)Werth VP, Hejazi E, Pena SM, Haber JS, Okawa J, et al: A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. Ann Rheum Dis 77(Suppl 2): 763, 2018
22)Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV: Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford) 58: 1011-1015, 2019
23)Chen Z, Wang X, Ye S: Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381: 291-293, 2019
24)Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working Group: 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 28: 87-99, 2018
25)Watanabe Y, Uruha A, Suzuki S, Nakahara J, Hamanaka K, et al: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87: 1038-1044, 2016
26)Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L: Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 62: 1328-1334, 2010
27)Kassardjian CD, Lennon VA, Alfugham NB, Mahler M, Milone M: Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol 72: 996-1003, 2015
28)Mammen AL, Tiniakou E: Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med 373: 1680-1682, 2015
29)Kadoya M, Hida A, Hashimoto Maeda M, Taira K, Ikenaga C, et al: Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm 3: e290, 2016［doi:10.1212/NXI.0000000000000290］
30)Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, et al: In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis 78: 131-139, 2019
31)Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, et al: Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol 81: 538-548, 2017
32)Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, et al: Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford) 53: 379-380, 2014
掲載誌情報
